Anti-NSE for IHC / ENO2 / Gamma-enolase, clone MSVA-451M

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Gamma-enolase (ENO2), also known as neuron-specific enolase (NSE), is a glycolytic enzyme predominantly expressed in neurons and neuroendocrine cells, where it serves as a well-established marker of neuronal differentiation and neuroendocrine lineage. It is localized to the cytoplasm and is widely used in immunohistochemistry to identify cells of neuronal and neuroendocrine origin. Gamma-enolase Antibody for IHC is commonly applied to formalin-fixed, paraffin-embedded tissues to visualize these cell populations, where its characteristic cytoplasmic HRP-DAB brown staining pattern enables clear identification of neuronal structures and neuroendocrine components in tissue sections. For detection of neuron-specific enolase (NSE), also known as gamma enolase, across tissue types, see our NSE antibody.Gamma-enolase antibody, also referred to as ENO2 antibody or NSE antibody in the literature, recognizes a cytoplasmic protein with highly restricted expression in neuronal and neuroendocrine cells. This Gamma-enolase Antibody for IHC is specifically optimized for Tissue Microarray (TMA)-based immunohistochemistry, enabling standardized, high-throughput evaluation of ENO2 expression across large panels of normal and cancer tissues. In normal tissue TMAs, strong and consistent cytoplasmic staining is observed in neuronal populations of the central nervous system, including cerebellum and cerebral cortex, as well as in neuroendocrine cells within select tissues, while most non-neuronal tissues remain largely negative, providing excellent contrast for interpretation.In cancer tissue microarrays, Gamma-enolase expression is prominently detected in tumors with neuroendocrine differentiation, where diffuse and often intense cytoplasmic staining highlights tumor cells of neuronal or neuroendocrine origin. This includes strong immunoreactivity in neuroendocrine tumors and subsets of carcinomas exhibiting neuroendocrine features. The clear distinction between ENO2-positive tumor cells and surrounding negative stromal or epithelial components supports the use of Gamma-enolase Antibody for IHC in identifying neuroendocrine differentiation and assisting in tumor classification and diagnostic workflows. The ability to evaluate these lineage-specific staining patterns across hundreds of TMA cores enhances reproducibility and comparative interpretation across tumor types.Tissue Microarray (TMA) analysis enables side-by-side comparison of ENO2 expression across diverse tissue types under identical staining conditions, demonstrating highly reproducible cytoplasmic staining in neuronal and neuroendocrine tissues alongside minimal background in non-expressing regions. The performance of clone MSVA-451M in TMA-based IHC highlights its ability to generate strong, well-defined staining across a broad range of tissues, supporting its use in large-scale immunohistochemistry studies, biomarker validation, and tissue profiling applications. Observed staining patterns align with established ENO2 biology and reference datasets such as the Human Protein Atlas.This antibody targets Gamma-enolase in research applications requiring precise and interpretable immunohistochemical detection of neuronal and neuroendocrine markers in FFPE tissue sections, making it well suited for studies of neuroendocrine tumors, neuronal differentiation, and tissue-specific expression analysis.This antibody is part of the Gamma-enolase antibody collection, where additional ENO2 antibodies for immunohistochemistry can be explored.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.